On March 18, 2026, XOMA Royalty Corporation (NASDAQ: XOMA) announced its financial results for the fiscal year ended December 31, 2025, showcasing a robust performance with over $50 million in cash receipts. This includes $33.6 million in royalties and $16.9 million in milestone payments, marking a 9% increase in total receipts compared to the previous year, with royalties alone surging by 68%. The company has strategically added 22 assets to its portfolio, including five programs currently in Phase 2 or Phase 3 development, which positions XOMA for future growth. Additionally, XOMA executed a stock buyback program, repurchasing 648,048 shares for a total of $16 million, reflecting its commitment to returning value to shareholders. The company completed seven acquisitions, accumulating $11.7 million in non-dilutive capital and gaining economic interests in potential milestone payments and royalties from partnered programs. Looking ahead, XOMA anticipates key pipeline events in 2026, including Phase 2b data from volixibat and Phase 3 data from ersodetug, alongside potential regulatory decisions on marketing authorization applications for OJEMDA and MIPLYFFA. The company’s CEO, Owen Hughes, emphasized the focus on enhancing portfolio optionality and driving shareholder value through innovative strategies. The webcast discussing these results is scheduled for March 18, 2026, at 8:00 am Eastern Time.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.